Inventiva (NASDAQ:IVA) Stock Price Down 6.3% – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price was down 6.3% on Thursday . The stock traded as low as $4.79 and last traded at $4.7810. Approximately 80,131 shares changed hands during trading, a decline of 81% from the average daily volume of 431,862 shares. The stock had previously closed at $5.10.

Analyst Upgrades and Downgrades

IVA has been the subject of several recent research reports. UBS Group began coverage on Inventiva in a report on Wednesday. They set a “buy” rating and a $12.00 price target for the company. Wolfe Research raised Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Wall Street Zen upgraded Inventiva to a “hold” rating in a research note on Saturday, October 18th. HC Wainwright raised their target price on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Inventiva Stock Performance

The business has a 50-day simple moving average of $4.30 and a 200-day simple moving average of $4.45.

Institutional Investors Weigh In On Inventiva

Several institutional investors have recently made changes to their positions in the company. Millennium Management LLC bought a new position in Inventiva during the 3rd quarter valued at about $649,000. NewEdge Advisors LLC bought a new stake in Inventiva in the third quarter worth about $116,000. Creative Planning purchased a new position in shares of Inventiva during the second quarter valued at approximately $32,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after buying an additional 9,212 shares during the last quarter. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.